JZJiahui Zhang

Jiahui Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jiahui Zhang has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Hong Cai

    Department of Nephrology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P.R. China

    1 shared publication
  • Jia Xia

    Molecular Cell Lab for Kidney Disease, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University

    1 shared publication
  • Jiajia Wu

    Department of Nephrology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P.R. China

    1 shared publication
  • Jie Wang

    Department of Biochemistry and Molecular Cell Biology, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Shanghai Jiao Tong University School of Medicine, Shanghai, P.R. China

    1 shared publication
  • Shan Mou

    Department of Nephrology, Ren Ji Hospital, School of Medicine Shanghai Jiao Tong University Shanghai China

    1 shared publication
  • Wen Yang

    Cancer Research Center, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China

    1 shared publication

Latest Publications

  • Open Access

    Repair of Isoaspartyl Residues by PCMT1 and Kidney Fibrosis

    by Jia Xia, Yutong Hou, Jie Wang, Jiahui Zhang, Jiajia Wu, Xiang Yu, Hong Cai, Wen Yang, Yingjie Xu, Shan Mou

    Key Points: Protein L-isoaspartyl/D-aspartyl methyltransferase (PCMT1) expression was lower in fibrotic kidney tubule, and tubule-specific deficiency worsened the pathogenesis and progression of CKD. Decreased PCMT1 levels inversely correlated with kidney function, highlighting its potential as a diagnostic and therapeutic target. PCMT1 enzymatically regulated the deamidation and protein stability of TGF- β receptor 2, inhibited TGF- β 1/Smad signaling, and impeded the profibrotic process. Background: Kidney fibrosis, the excessive accumulation and dysregulated remodeling of the extracellular matrix, is the principal pathophysiologic process in CKD. Protein L-isoaspartyl/D-aspartyl methyltransferase (PCMT1) is crucial in repairing post-translational modifications of L-isoaspartyl residues, which are important for extracellular matrix proteins because of their low turnover rate and susceptibility to accelerating factors. This study aimed to reveal a novel role of PCMT1 in kidney fibrosis. Methods: Kidney tissues from mice and humans were evaluated for PCMT1 expression and its association with fibrosis and kidney function. PCMT1's effects on the TGF- β 1/Smad signaling were analyzed, and its functional role was assessed in tubule-specific Pcmt1 knockout murine models of kidney fibrosis. The ability of secreted PCMT1 to repair L-isoaspartyl residues on the ectodomain of TGF- β receptor 2 (TGFBR2) was investigated using immunoprecipitation, gene lentivirus overexpression or knockout, and post-translational modification mass spectrometry. Results: PCMT1 expression was decreased in the tubules of human kidney biopsies from patients with CKD and murine fibrosis models. Renal tubule-specific PCMT1 deficiency in murine kidney fibrosis models worsened tubular injury, extracellular matrix protein deposition, myofibroblast activation, and TGF- β 1/Smad signaling overactivation. Mechanistically, PCMT1 was unconventionally secreted and enzymatically inhibited TGF- β 1–induced extracellular matrix protein deposition in vitro . PCMT1 interacted with TGFBR2, reversing N63 deamidation on its ectodomain, which triggered TGFBR2 ubiquitination and degradation. PCMT1 supplementation in kidneys decreased TGFBR2 levels, attenuated TGF- β 1/Smad overactivation, and impeded the profibrotic process. Conclusions: Our study highlights the importance of PCMT1 in maintaining extracellular matrix homeostasis and mitigating kidney fibrosis by regulating TGFBR2 deamidation and its protein stability, suppressing the TGF- β 1/Smad signaling.